Shots: Lilly and Incyte reported that the US FDA has extended the review period of sNDA for baricitinib to treat adults with mod. to sev. atopic AD The FDA has extended the action date, allowing the time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA. The […]Read More
Shots: The agreement strengthens the ongoing collaboration b/w the companies signed in 2018 to commercialize Alvotech’s biosimilar portfolio in Japan Fuji Pharma currently owns a minority stake in Alvotech and now can enter new therapeutic areas following the agreement With the extension of the agreement, Fuji Pharma has a leading biosimilar pipeline in Japan. Fuji […]Read More
Shots: Novartis reported that the US FDA has extended its review of sBLA for ofatumumab (OMB 157) to treat patients with RMS. The company anticipates the regulatory action in Sept’2020 Novartis works with the US FDA to continue the review for ofatumumab (SC) in RMS, for the approval in the US with expected EU approval […]Read More
Shots: Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones […]Read More
Shots: SVI to receive development milestones, royalties and option exercise fee. Janssen to exercise its option and will be responsible for all development of small molecule modulators of microglial function and inflammation for Alzheimer’s disease In Aug’2017, Janssen collaborated with SVI to develop & commercialize small molecule modulators of microglial function and inflammation focusing the […]Read More
Shots: The extended agreement allows Cantargia to create and use additional CHO cell lines engineered utilizing BioWa’s POTELLIGENT technology and to develop and commercialize CAN04 developed via CHO cell lines In 2015, Cantargia signed an agreement with BioWa’s technology in advancing its CAN04 to P-IIa clinical study for the treatment of non-small cell lung cancer […]Read More
Shots: Merck exercises its option to extend its Feb,2015 agreement with NGM for development and commercialization of novel biologics therapies. NGM to receive $20M as an extension fee for R&D activities during the two-year extension period in Mar 2021 & 2022 As part of the collaboration, in Jan,2019 Merck in-licensed NGM’s NASH therapy NGM313 (MK-3655), […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
